Wall Street analysts expect Allakos Inc (NASDAQ:ALLK) to post ($0.46) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Allakos’ earnings, with the highest EPS estimate coming in at ($0.42) and the lowest estimate coming in at ($0.50). Allakos reported earnings of ($0.35) per share during the same quarter last year, which would suggest a negative year over year growth rate of 31.4%. The business is scheduled to issue its next earnings results on Thursday, March 12th.
On average, analysts expect that Allakos will report full year earnings of ($1.83) per share for the current financial year, with EPS estimates ranging from ($1.91) to ($1.74). For the next financial year, analysts forecast that the firm will report earnings of ($2.44) per share, with EPS estimates ranging from ($2.58) to ($2.30). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Allakos.
Allakos (NASDAQ:ALLK) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.04).
Several research analysts have weighed in on ALLK shares. Zacks Investment Research downgraded shares of Allakos from a “buy” rating to a “hold” rating in a research report on Friday, August 16th. ValuEngine downgraded shares of Allakos from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Finally, William Blair reiterated a “buy” rating on shares of Allakos in a research report on Friday, August 9th.
ALLK traded down $3.45 during trading on Friday, hitting $72.72. The company’s stock had a trading volume of 258,400 shares, compared to its average volume of 435,451. Allakos has a one year low of $30.32 and a one year high of $92.84. The firm has a market cap of $3.24 billion, a PE ratio of -33.05 and a beta of -1.38. The business’s 50 day simple moving average is $73.05 and its 200-day simple moving average is $59.64.
Hedge funds have recently made changes to their positions in the company. Bank of Montreal Can bought a new stake in shares of Allakos during the 2nd quarter valued at $63,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Allakos during the 2nd quarter valued at $281,000. Alps Advisors Inc. bought a new stake in shares of Allakos during the 2nd quarter valued at $3,894,000. SG Americas Securities LLC raised its position in shares of Allakos by 27.5% during the 2nd quarter. SG Americas Securities LLC now owns 4,819 shares of the company’s stock valued at $209,000 after purchasing an additional 1,040 shares during the period. Finally, Requisite Capital Management LLC bought a new stake in shares of Allakos during the 3rd quarter valued at $786,000. Hedge funds and other institutional investors own 58.47% of the company’s stock.
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Featured Article: Capital gains and your 401(k) or IRA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.